IP Library Granted Patent US 8,841,114
Granted Patent B2
US 8,841,114 · App. 13/392,601 · Granted Sep 23, 2014

Genetically modified organism for the production of lipids

Inventors: Christine Lang (Berlin, DE); Andreas Raab (Berlin, DE)
Assignee: OrganoBalance GmbH
C12N9/1007C12P7/6436C12Y203/0102C12N9/1029A61Q19/00C12P33/00C12N9/0071C12P5/007C12P7/6463C12Y101/01034C12Y203/01026Y02E50/343A61K8/99
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,841,114
App. No.
13/392,601
Granted
Sep 23, 2014
Kind
B2
Abstract

The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA: sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.

Claims (9)

1. An isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA: sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) is reduced or abolished in comparison with a corresponding wildtype organism, and wherein the activity of HMG-CoA-reductase (3-hydroxy-3-methyl-glutaryl-Coenzyme-A-reductase, EC1.1.1.34), is increased in comparison with the corresponding wildtype organism, and wherein the activities and/or amounts of heme-activated protein HAP4p and/or SNF1-activated kinase SAKI p are increased and/or wherein the activities and/or amounts of regenerating islet-derived 1 pseudogene REGI p and/or few lipid dropplets protein 1 FLDI p are decreased or abolished.

2. The organism of claim 1 ,

wherein at least a first lipid accumulated in lipid particles of the corresponding wild type organism, is no longer synthesized, and

wherein a second lipid being different from the first lipid is accumulated in the lipid particles of the genetically modified organism.

3. The organism of claim 2 , wherein the second lipid is sterol or steroid and

wherein the sterol is cholesterol, a cholesterol derivative, 7-dehydro-cholesterol, lanosterol, a lanosterol derivative, zymosterol, a zymosterol derivative, lathosterol, a lathosterol derivative, cucurbitacin, a cucurbatin derivative, episterol, a episterol derivative, teasterone, a teasterone derivative, castasterone, a castasterone derivative, typhasterol, a typhasterol derivative, cathasterone, a cathasterone derivative, cycloeucalenol, a cycloeucalenol derivative, sitosterol, a sitosterol derivative, isofucosterol, a isofucosterol derivative, fucosterol, a fucosterol derivative, gorgosterol, a gorgosterol derivative, ergosterol, an ergosterol derivative, stigmasterol or a stigmasterol derivative, or

wherein the steroid is androsterone, an androsterone derivative, testosterone, a testosterone derivative, androstenediol, an androstenediol derivative, androstenedione, an androstenedione derivative, calusterone, a calusterone derivative, methandriol, a methandriol derivative, bolasterone, a bolasterone derivative, epiandrosterone, an epiandrosterone derivative, mestanolone, a mestanolone derivative, stanolone, a stanolone derivative, stenbolone, a stenbolone derivative, epitestosterone, an epitestosterone derivative, Cortisol, a Cortisol derivative, aldosterone, an aldosterone derivative, pregnenolone, a pregnenolone derivative, cortisone, a cortisone derivative, corticosterone, a corticosterone derivative, norethindrone, a norethindrone derivative, urocortisol or an urocortisol derivative.

4. The organism of claim 1 ,

wherein the organism is an eukaryotic organism.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2017
From: ORGANOBALANCE GMBH
To: NOVOZYMES A/S
Reel/Frame 043309/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2012
From: LANG, CHRISTINE; RAAB, ANDREAS
To: ORGANOBALANCE GMBH
Reel/Frame 027862/0341 →
Priority Claims (1)
EP 09075393 · Aug 26, 2009 · regional
Continuity (1)
Related Publication 20120156249A1 · Jun 21, 2012